The Research Pharmacy (RP) Core provides a full service facility that prepares agents developed by MSK researchers to be used as investigational drugs in preclinical or clinical studies. The Core comprises three principal groups: the Pharmaceutical Product Facility (PPF) for drug formulation/stability and preparation; the Clinical Grade Production (CGP) Facility for bulk product manufacturing, purification, and vialing; and the Pharmacy Investigational Drug Service (PIDS), which provides a service to develop, procure, prepare, and validate the preparation, packaging, and distribution of investigational drugs for clinical use. The Core services include, but are not limited to, formulation, analysis, and evaluation of drug release rates; prediction of interactions; and determinations of compatibility and physical stability of medications. Owing to the infrastructure of the Core, MSK has been able to bring into early phase clinical trials multiple distinct types of pharmacologic agents, including traditional small molecules, radiopharmaceuticals, and vaccines. The broad range of services and collaborative work provided by the combined PPF/CGP/PIDS groups within the RP Core has supported the research of 33 investigators from 12 Department in 37 IRB-approved protocols. The work of the Core has contributed to 34 publications in leading general interest or cancer journals. For example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSK; this therapeutic antibody forms the backbone of the Center?s research program in neuroblastoma; and has now been validated as an effective treatment for children with refractory neuroblastoma. The Center?s large and complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical testing of vaccines against cancers including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-53
Application #
9631239
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
53
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Staehler, M; Motzer, R J; George, D J et al. (2018) Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 29:2098-2104
Cybulska, Paulina; Goss, Cheryl; Tew, William P et al. (2018) Corrigendum to ""Indications for and complications of transfusion and the management of gynecologic malignancies"" [Gynecol. Oncol. 146 (2017) 416-426]. Gynecol Oncol 148:235
Giulino-Roth, Lisa; O'Donohue, Tara; Chen, Zhengming et al. (2018) Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 59:1861-1870
Kidwell, Kelley M; Postow, Michael A; Panageas, Katherine S (2018) Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. Clin Cancer Res 24:730-736
Dean, Jamie; Wong, Kee; Gay, Hiram et al. (2018) Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy. Clin Transl Radiat Oncol 8:27-39
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Morales, K A; Arevalo-Perez, J; Peck, K K et al. (2018) Differentiating Atypical Hemangiomas and Metastatic Vertebral Lesions: The Role of T1-Weighted Dynamic Contrast-Enhanced MRI. AJNR Am J Neuroradiol 39:968-973
Lee, Sang Ho; Rimner, Andreas; Gelb, Emily et al. (2018) Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102:718-726
Ramaswamy, Kavitha; Forbes, Lauren; Minuesa, Gerard et al. (2018) Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun 9:110

Showing the most recent 10 out of 8799 publications